Selective Inhibition of MMP-2 Does Not Alter Neurological Recovery after Spinal Cord Injury

Ming Gao, Haoqian Zhang, Alpa Trivedi, Kiran V. Mahasenan, Valerie A. Schroeder, William R. Wolter, Mark A. Suckow, Shahriar Mobashery, Linda J. Noble-Haeusslein, Mayland Chang

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Matrix metalloproteinase (MMP)-2 knockout (KO) mice show impaired neurological recovery after spinal cord injury (SCI), suggesting that this proteinase is critical to recovery processes. However, this finding in the KO has been confounded by a compensatory increase in MMP-9. We synthesized the thiirane mechanism-based inhibitor ND-378 and document that it is a potent (nanomolar) and selective slow-binding inhibitor of MMP-2 that does not inhibit the closely related MMP-9 and MMP-14. ND-378 crosses the blood-spinal cord barrier, achieving therapeutic concentrations in the injured spinal cord. Spinal-cord injured mice treated with ND-378 showed no change in long-term neurological outcomes, suggesting that MMP-2 is not a key determinant of locomotor recovery.

Original languageEnglish (US)
Pages (from-to)1482-1487
Number of pages6
JournalACS Chemical Neuroscience
Issue number11
StatePublished - Nov 16 2016

Bibliographical note

Publisher Copyright:
© 2016 American Chemical Society.


  • MMP-2
  • ND-378
  • brain distribution
  • spinal cord injury


Dive into the research topics of 'Selective Inhibition of MMP-2 Does Not Alter Neurological Recovery after Spinal Cord Injury'. Together they form a unique fingerprint.

Cite this